MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
SAB Biotherapeutics Inc (NASDAQ:SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.
It has recently received FDA Breakthrough Therapy and Fast Track Designations.
What Happened: The data was presented at the AVG conference hosted by the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV).
SAB-176 is a fully human, broadly neutralizing immunoglobulin antibody therapeutic designed to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised.
Results: In a Phase 2a challenge clinical trial, healthy adults (n=60) were given a 25 mg/kg dose of SAB-176 or placebo after being inoculated with H1N1.
Results showed that SAB-176 was safe, well-tolerated, and demonstrated a significant reduction in viral load compared to placebo and symptom reduction.
A preclinical study in mice indicated that the combination of low doses of SAB-176 and oseltamivir (Tamiflu) protected against a lethal dose of H1N1 comparable to a high dose of oseltamivir alone.
Tamiflu is an antiviral medication from Genentech, a Roche Holdings AG (OTC: RHHBY) company.
Price Action: SABS shares closed at $0.87 on Wednesday.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!